Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7063477 | 0.81 | ADORA1 (0.46) | ADORA1NT5EAHCY | |
| SCHEMBL7066965 | 0.80 | ADORA1 (0.43) | ADORA1NT5EAHCY | |
| SCHEMBL9218681 | 0.72 | ADORA1 (0.44) | ADORA1AHCYTRPM2 | |
| SCHEMBL7065334 | 0.71 | P2RY12 (0.35) | ADORA1P2RY12 | |
| SCHEMBL8972156 | 0.70 | ADORA1 (0.41) | ADORA1NT5EEGFRAHCYP2RY12 | |
| SCHEMBL7251215 | 0.70 | P2RY12 (0.34) | ADORA1P2RY12 | |
| SCHEMBL7063493 | 0.69 | P2RY12 (0.34) | ADORA1P2RY12 | |
| SCHEMBL7251726 | 0.69 | P2RY12 (0.33) | ADORA1NT5EP2RY12 | |
| SCHEMBL8144937 | 0.68 | TYMP (0.39) | ADORA1NT5EEGFRP2RX3P2RX4 | |
| SCHEMBL7063505 | 0.68 | HINT1 (0.38) | NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040126792-A1 | Synthesis and applications of trinucleotide pCpCpA-3'-NH-aminoacyl derivatives | UNIVERSITY OF MASSACHUSETTS | 2004-07-01 | — | — | US | disclosed |
| WO-2004026266-A2 | SYNTHESIS AND APPLICATIONS OF TRINUCLEOTIDE pCpCpA-3′-NH-AMINOACYL DERIVATIVES | UNIVERSITY OF MASSACHUSETTS (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040126792-A1 | Synthesis and applications of trinucleotide pCpCpA-3'-NH-aminoacyl derivatives | RNGTT, NOP2, NPEPPS | ADORA1 3491/4885NT5E 811/4885EGFR 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.